Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M. Machover D, et al. Among authors: brienza s. Ann Oncol. 1996 Jan;7(1):95-8. doi: 10.1093/oxfordjournals.annonc.a010489. Ann Oncol. 1996. PMID: 9081400 Free article. Clinical Trial.
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F. Giacchetti S, et al. Among authors: brienza s. Ann Oncol. 1999 Jun;10(6):663-9. doi: 10.1023/a:1008347829017. Ann Oncol. 1999. PMID: 10442188 Free article. Clinical Trial.
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Brienza S, Bensmaïne MA, Soulié P, Louvet C, Gamelin E, François E, Ducreux M, Marty M, André T, de Braud F, Bleiberg H, Ségal V, Itzhaki M, Cvitkovic E. Brienza S, et al. Ann Oncol. 1999 Nov;10(11):1311-6. doi: 10.1023/a:1008319600648. Ann Oncol. 1999. PMID: 10631458 Free article. Clinical Trial.
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Metzger G, Massari C, Etienne MC, Comisso M, Brienza S, Touitou Y, Milano G, Bastian G, Misset JL, Lévi F. Metzger G, et al. Among authors: brienza s. Clin Pharmacol Ther. 1994 Aug;56(2):190-201. doi: 10.1038/clpt.1994.123. Clin Pharmacol Ther. 1994. PMID: 8062496 Clinical Trial.
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
Bensmaïne, de Gramont A, Brienza S, Marty M, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Bleuzen P, Simon J, Cvitkovic E. Bensmaïne, et al. Among authors: brienza s. Eur J Cancer. 2000 Dec;36(18):2335-43. doi: 10.1016/s0959-8049(00)00305-1. Eur J Cancer. 2000. PMID: 11094307 Clinical Trial.
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E. Bensmaïne MA, et al. Among authors: brienza s. Br J Cancer. 2001 Aug 17;85(4):509-17. doi: 10.1054/bjoc.2001.1953. Br J Cancer. 2001. PMID: 11506488 Free PMC article. Clinical Trial.
49 results